Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

51 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prospective Clinical Integration of an Amplicon-Based Next-Generation Sequencing Method to Select Advanced Non-Small-Cell Lung Cancer Patients for Genotype-Tailored Treatments.
Zugazagoitia J, Rueda D, Carrizo N, Enguita AB, Gómez-Sánchez D, Díaz-Serrano A, Jiménez E, Mérida A, Calero R, Lujan R, De Miguel E, Gámez P, Díaz-Hellín V, Nuñez JA, Iglesias L, Ferrer I, Paz-Ares L, Ponce-Aix S. Zugazagoitia J, et al. Clin Lung Cancer. 2018 Jan;19(1):65-73.e7. doi: 10.1016/j.cllc.2017.06.008. Epub 2017 Jun 23. Clin Lung Cancer. 2018. PMID: 28780976
Clinical utility of plasma-based digital next-generation sequencing in oncogene-driven non-small-cell lung cancer patients with tyrosine kinase inhibitor resistance.
Zugazagoitia J, Gómez-Rueda A, Jantus-Lewintre E, Isla D, Camps C, Ramos I, Trigo JM, Bernabé R, Juan-Vidal O, Sanchez-Torres JM, García-Campelo R, Provencio M, Felip E, de Castro J, Faull I, Lanman RB, Ponce-Aix S, Paz-Ares L, Garrido P. Zugazagoitia J, et al. Lung Cancer. 2019 Aug;134:72-78. doi: 10.1016/j.lungcan.2019.05.032. Epub 2019 May 30. Lung Cancer. 2019. PMID: 31319999
Tumor mutational burden assessment in non-small-cell lung cancer samples: results from the TMB2 harmonization project comparing three NGS panels.
Ramos-Paradas J, Hernández-Prieto S, Lora D, Sanchez E, Rosado A, Caniego-Casas T, Carrizo N, Enguita AB, Muñoz-Jimenez MT, Rodriguez B, Perez-Gonzalez U, Gómez-Sánchez D, Ferrer I, Ponce Aix S, Nuñez Buiza Á, Garrido P, Palacios J, Lopez-Rios F, Garrido-Martin EM, Paz-Ares L. Ramos-Paradas J, et al. J Immunother Cancer. 2021 May;9(5):e001904. doi: 10.1136/jitc-2020-001904. J Immunother Cancer. 2021. PMID: 33963008 Free PMC article.
Analysis of mismatch repair (MMR) proteins expression in a series of malignant pleural mesothelioma (MPM) patients.
Cedrés S, Ponce-Aix S, Iranzo P, Callejo A, Pardo N, Navarro A, Martinez-Marti A, Gómez-Abecia S, Zucchiatti AC, Sansano I, Enguita AB, Miquel JM, Viaplana C, Dienstmann R, Paz-Ares L, Felip E. Cedrés S, et al. Clin Transl Oncol. 2020 Aug;22(8):1390-1398. doi: 10.1007/s12094-019-02275-9. Epub 2020 Jan 8. Clin Transl Oncol. 2020. PMID: 31916017
Randomised phase 2 study of pembrolizumab plus CC-486 versus pembrolizumab plus placebo in patients with previously treated advanced non-small cell lung cancer.
Levy BP, Giaccone G, Besse B, Felip E, Garassino MC, Domine Gomez M, Garrido P, Piperdi B, Ponce-Aix S, Menezes D, MacBeth KJ, Risueño A, Slepetis R, Wu X, Fandi A, Paz-Ares L. Levy BP, et al. Eur J Cancer. 2019 Feb;108:120-128. doi: 10.1016/j.ejca.2018.11.028. Epub 2019 Jan 14. Eur J Cancer. 2019. PMID: 30654297 Clinical Trial.
51 results